Sutro Biopharma (STRO) Short term Debt (2017 - 2023)

Sutro Biopharma (STRO) has 6 years of Short term Debt data on file, last reported at $4.1 million in Q4 2023.

• For the quarter ending Q4 2023, Short term Debt fell 67.51% year-over-year to $4.1 million; the trailing twelve-month figure through Dec 2023 stood at $4.1 million (down 67.51% YoY), and the FY2023 full-year result was $4.1 million, down 67.51% from the prior year.
• Short term Debt retreated to $4.1 million in Q4 2023, from $7.1 million in the prior quarter.
• In the past five years, Short term Debt ranged from a high of $13.2 million in Q1 2023 to a low of $1.0 million in Q4 2019.
• A 4-year average of $8.1 million and a median of $7.1 million in 2023 frame the typical range for Short term Debt.
• Across the five-year window, Short term Debt slumped 78.83% in 2019 and jumped 300.0% in 2022, its largest moves.
• Tracing STRO's Short term Debt over 4 years: stood at $1.0 million in 2019, then soared by 837.5% to $9.4 million in 2021, then jumped by 33.33% to $12.5 million in 2022, then sank by 67.51% to $4.1 million in 2023.
• Business Quant data shows STRO's Short term Debt at $4.1 million in Q4 2023, $7.1 million in Q3 2023, and $10.2 million in Q2 2023.